Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: Novel insights into the role of deubiquitination in cell signaling

Human Mutation

Volumn 30, Issue 7, 2009, Pages 1025-1036

  Blake, Patrick W ^a,b   Toro, Jorge R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Brooke Spiegler; CYLD; Cylindroma; Familial cylindromatosis; Spiradenoma; Trichoepithelioma

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; PROTEIN CYLINDROMATOSIS; STRESS ACTIVATED PROTEIN KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CYLINDROMA; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE STRUCTURE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; UBIQUITINATION;

ANIMALS; HUMANS; MUTATION; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

ANIMALIA;

EID: 67649672157     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.21024     Document Type: Review

References (121)

1. Almeida S, Maillard C, Itin P, Hohl D, Huber M. 2008. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity. J Invest Dermatol 128:587-593. (Pubitemid 351252652)
2. Alsaad KO, Obaidat NA, Ghazarian D. 2007. Skin adnexal neoplasms - Part 1: An approach to tumours of the pilosebaceous unit. J Clin Pathol 60:129-144. (Pubitemid 46245777)
3. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-3402. (Pubitemid 27359211)
4. Anderson DE, Howell JB. 1976. Epithelioma adenoides cysticum: genetic update. Br J Dermatol 95:225-232.
5. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy Jr. JD, Kuehl WM, Staudt LM. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115-130. (Pubitemid 47199123)
6. Antonescu CR, Terzakis JA. 1997. Multiple malignant cylindromas of skin in association with basal cell adenocarcinoma with adenoid cystic features of minor salivary gland. J Cutan Pathol 24:449-453. (Pubitemid 27374509)
7. Avvakumov GV, Walker JR, Xue S, Finerty PJ, Jr, Mackenzie F, Newman EM, Dhe-Paganon S. 2006. Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J Biol Chem 281:38061-38070. (Pubitemid 46042109)
8. Ayhan M, Adanali G, Senen D, Gorgu M, Erdogan B. 2001. Rarely seen cutaneous lesions in an elderly patient: Malignant transformation of multiple trichoepithelioma. Ann Plast Surg 47:98-99. (Pubitemid 32623165)
9. Baican A, Has C, Crisan C, Orasan R, Petrescu M, Machet L. 1998. Multiple cutaneous cylindromas associated with parotid and submandibular gland cylindromas. Ann Dermatol Venereol 125:909-911. (Pubitemid 29029419)
10. Biggs PJ, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y, Easton DF, Burn J, Stratton MR. 1995. Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet 11:441-443.
11. Biggs PJ, Chapman P, Lakhani SR, Burn J, Stratton MR. 1996. The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene 12:1375-1377. (Pubitemid 26127270)
12. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. 2000. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25:160-165. (Pubitemid 30394985)
13. Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME, Celebi JT. 2005. Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation. J Invest Dermatol 124:919-920. (Pubitemid 40629091)
14. Braun-Falco M, Bonel H, Ring J, Hein R. 2003. Linear spiradenoma with focal malignant transformation. J Eur Acad Dermatol Venereol 17:308-312. (Pubitemid 36575655)
15. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424:797-801. (Pubitemid 37021711)
16. Choi HR, Batsakis JG, Callender DL, Prieto VG, Luna MA, El-Naggar AK. 2002. Molecular analysis of chromosome 16q regions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma? Am J Surg Pathol 26:778-783.
17. Chou SC, Lin SL, Tseng HH. 2004. Malignant eccrine spiradenoma: a case report with pulmonary metastasis. Pathol Int 54:208-212. (Pubitemid 38698134)
18. Chu L, Gu J, He Z, Xiao T, Liu X. 2006. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma. Cancer Biol Ther 5:615-622. (Pubitemid 44024715)
19. Cooper PH, Frierson Jr HF, Morrison AG. 1985. Malignant transformation of eccrine spiradenoma. Arch Dermatol 121:1445-1448. (Pubitemid 16216789)
20. Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T, Gurbuz Y, Nikolaus S, Albrecht M, Hampe J, Lucius R, Kloppel G, Eickhoff H, Lehrach H, Lengauer T, Schreiber S. 2005. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2:e199. (Pubitemid 46179249)
21. Courtois G. 2008. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more. Cell Mol Life Sci 65:1123-1132.
22. Crotty K, Dutta B, Hogan P. 2003. Multiple trichoepitheliomas in a mother and daughter. Australas J Dermatol 44:270-272. (Pubitemid 37518554)
23. De Francesco V, Frattasio A, Pillon B, Stinco G, Scott CA, Trotter D, Patrone P. 2005. Carcinosarcoma arising in a patient with multiple cylindromas. Am J Dermatopathol 27:21-26. (Pubitemid 40189019)
24. Durani BK, Kurzen H, Jaeckel A, Kuner N, Naeher H, Hartschuh W. 2001. Malignant transformation of multiple dermal cylindromas. Br J Dermatol 145:653-656. (Pubitemid 36138932)
25. Engel CJ, Meads GE, Joseph NG, Stavraky W. 1991. Eccrine spiradenoma: a report of malignant transformation. Can J Surg 34:477-480.
26. Espana A, Garcia-Amigot F, Aguado L, Garcia-Foncillas J. 2007. A novel missense mutation in the CYLD gene in a Spanish family with multiple familial trichoepithelioma. Arch Dermatol 143:1209-1210. (Pubitemid 47443384)
27. Fisher GH, Geronemus RG. 2006. Treatment of multiple familial trichoepitheliomas with a combination of aspirin and a neutralizing antibody to tumor necrosis factor alpha: a case report and hypothesis of mechanism. Arch Dermatol 142:782-783. (Pubitemid 43920650)
28. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT. 2008. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep 9:930-936.
29. Fukuda M, Hiroi M, Suzuki S, Ohmori Y, Sakashita H. 2008. Loss of CYLD might be associated with development of salivary gland tumors. Oncol Rep 19:1421-1427.
30. Gao J, Huo L, Sun X, Liu M, Li D, Dong JT, Zhou J. 2008. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 283:8802-8809.
31. Gerretsen AL, van der Putte SC, Deenstra W, van Vloten WA. 1993. Cutaneous cylindroma with malignant transformation. Cancer 72:1618-1623. (Pubitemid 23249288)
32. Hacker H, Karin M. 2006. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006:re13.
33. Haglund K, Dikic I. 2005. Ubiquitylation and cell signaling. EMBO J 24:3353-3359. (Pubitemid 41486773)
34. Harada H, Hashimoto K, Ko MS. 1996. The gene for multiple familial trichoepithelioma maps to chromosome 9p21. J Invest Dermatol 107:41-43. (Pubitemid 26236092)
35. Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A, Furuya T, Tangoku A, Oka M, Sasaki K. 2004. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 17:617-622. (Pubitemid 38715482)
36. Heinritz W, Grunewald S, Strenge S, Schutz A, Froster UG, Glander HJ, Paasch U, Simon JC. 2006. A case of Brooke-Spiegler syndrome with a new mutation in the CYLD gene. Br J Dermatol 154:992-994.
37. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. 2007. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28:21-27. (Pubitemid 44942623)
38. Hirai Y, Kawamata Y, Takeshima N, Furuta R, Kitagawa T, Kawaguchi T, Hasumi K, Sugai S, Noda T. 2004. Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix. Int J Oncol 24:977-986.
39. Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE, Shi Y. 2002. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111:1041-1054. (Pubitemid 36050118)
40. Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gurer MA, Celebi JT. 2003. A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome. J Invest Dermatol 121:732-734. (Pubitemid 37239114)
41. Hu M, Li P, Song L, Jeffrey PD, Chenova TA, Wilkinson KD, Cohen RE, Shi Y. 2005. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J 24:3747-3756. (Pubitemid 41581691)
42. Huang TM, Chao SC, Lee JY. 2009. A novel splicing mutation of the CYLD gene in a Taiwanese family with multiple familial trichoepithelioma. Clin Exp Dermatol 34:77-80.
43. Ishikawa M, Nakanishi Y, Yamazaki N, Yamamoto A. 2001. Malignant eccrine spiradenoma: a case report and review of the literature. Dermatol Surg 27:67-70. (Pubitemid 32107623)
44. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. 2007. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110:3291-3300. (Pubitemid 350106322)
45. Jin W, Reiley WR, Lee AJ, Wright A, Wu X, Zhang M, Sun SC. 2007. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem 282:15884-15893. (Pubitemid 47093308)
46. Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC. 2008. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 118:1858-1866. (Pubitemid 351632388)
47. Johnson SC, Bennett RG. 1993. Occurrence of basal cell carcinoma among multiple trichoepitheliomas. J Am Acad Dermatol 28:322-326. (Pubitemid 23056279)
48. Jono H, Lim JH, Chen LF, Xu H, Trompouki E, Pan ZK, Mosialos G, Li JD. 2004. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 279:36171-36174. (Pubitemid 39128950)
49. Jungehulsing M, Wagner M, Damm M. 1999. Turban tumour with involvement of the parotid gland. J Laryngol Otol 113:779-783. (Pubitemid 29387160)
50. Kakagia D, Alexiadis G, Kiziridou A, Lambropoulou M. 2004. Brooke-Spiegler syndrome with parotid gland involvement. Eur J Dermatol 14:139-141. (Pubitemid 38738450)
51. Karin M, Cao Y, Greten FR, Li ZW. 2002. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310. (Pubitemid 37328783)
52. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M. 2005. Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol 27:27-33. (Pubitemid 40189020)
53. Kazakov DV, Magro G, Kutzner H, Spagnolo DV, Yang Y, Zaspa O, Mukensnabl P, Michal M. 2008. Spiradenoma and spiradenocylindroma with an adenomatous or atypical adenomatous component: a clinicopathological study of 6 cases. Am J Dermatopathol 30:436-441.
54. Kazakov DV, Zelger B, Rutten A, Vazmitel M, Spagnolo DV, Kacerovska D, Vanecek T, Grossmann P, Sima R, Grayson W, Calonje E, Koren J, Mukensnabl P, Danis D, Michal M. Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol (in press). [2009 Feb 3, Epub ahead of print]
55. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. 2007. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell 12:131-144. (Pubitemid 47208626)
56. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R. 2008. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123:552-560. (Pubitemid 351898412)
57. Koga T, Lim JH, Jono H, Ha UH, Xu H, Ishinaga H, Morino S, Xu X, Yan C, Kai H, Li JD. 2008. Tumor suppressor cylindromatosis acts as a negative regulator for streptococcus pneumoniae-induced NFAT signaling. J Biol Chem 283: 12546-12554.
58. Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, Barford D. 2008. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 29:451-464. (Pubitemid 351282537)
59. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. 2003. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801-805. (Pubitemid 37021712)
60. Lee DA, Grossman ME, Schneiderman P, Celebi JT. 2005. Genetics of skin appendage neoplasms and related syndromes. J Med Genet 42:811-819. (Pubitemid 41598188)
61. Lee KH, Kim JE, Cho BK, Kim YC, Park CJ. 2008. Malignant transformation of multiple familial trichoepithelioma: case report and literature review. Acta Derm Venereol 88:43-46. (Pubitemid 351212135)
62. Leonard N, Chaggar R, Jones C, Takahashi M, Nikitopoulou A, Lakhani SR. 2001. Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours. J Clin Pathol 54:689-692. (Pubitemid 32835416)
63. Lian F, Cockerell CJ. 2005. Cutaneous appendage tumors: familial cylindromatosis and associated tumors update. Adv Dermatol 21:217-234. (Pubitemid 41826752)
64. Liang YH, Gao M, Sun LD, Liu LJ, Cui Y, Yang S, Fan X, Wang J, Xiao FL, Zhang XJ. 2005. Two novel CYLD gene mutations in Chinese families with trichoepithelioma and a literature review of 16 families with trichoepithelioma reported in China. Br J Dermatol 153:1213-1215. (Pubitemid 41779580)
65. Liang YH, Sun CS, Ye XY, Zhang W, Yang S, Zhang XJ. 2008. Novel substitution and frameshift mutations of CYLD in two Chinese families with multiple familial trichoepithelioma. Br J Dermatol 158:1156-1158.
66. Lim JH, Jono H, Koga T, Woo CH, Ishinaga H, Bourne P, Xu H, Ha UH, Xu H, Li JD. 2007a. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS ONE 2:e1032.
67. Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, Xu H, Andalibi A, Feng XH, Zhu H, Huang Y, Zhang W, Weng X, Yan C, Yin Z, Briles DE, Davis RJ, Flavell RA, Li JD. 2007b. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27:349-360. (Pubitemid 47284927)
68. Lim JH, Ha UH, Woo CH, Xu H, Li JD. 2008a. CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol 11:2247-2256.
69. Lim JH, Ha U, Sakai A, Woo CH, Kweon SM, Xu H, Li JD. 2008b. Streptococcus pneumoniae synergizes with nontypeable Haemophilus influenzae to induce inflammation via upregulating TLR2. BMC Immunol 9:40.
70. Lv HL, Huang YJ, Zhou D, Du YF, Zhao XY, Liang YH, Quan C, Zhang H, Zhou FS, Gao M, Zhou L, Yang S, Zhang XJ. 2008. A novel missense mutation of CYLD gene in a Chinese family with multiple familial trichoepithelioma. J Dermatol Sci 50:143-146.
71. Ly H, Black MM, Robson A. 2004. Case of the Brooke-Spiegler syndrome. Australas J Dermatol 45:220-222. (Pubitemid 39487038)
72. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. 2006a. Cyld inhibits tumor cell proliferation by blocking bcl-3-dependent NF-kappaB signaling. Cell 125:665-677.
73. Massoumi R, Podda M, Fassler R, Paus R. 2006b. Cylindroma as tumor of hair follicle origin. J Invest Dermatol 126:1182-1184.
74. Massoumi R, Paus R. 2007. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays 29:1203-1214. (Pubitemid 350221789)
75. Michal M, Lamovec J, Mukensnabl P, Pizinger K. 1999. Spiradenocylindromas of the skin: tumors with morphological features of spiradenoma and cylindroma in the same lesion: report of 12 cases. Pathol Int 49:419-425. (Pubitemid 29309672)
76. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. 2005. A genomic and functional inventory of deubiquitinating enzymes. Cell 123:773-786. (Pubitemid 41721026)
77. Obaidat NA, Alsaad KO, Ghazarian D. 2007. Skin adnexal neoplasms - Part 2: An approach to tumours of cutaneous sweat glands. J Clin Pathol 60:145-159. (Pubitemid 46245778)
78. Oiso N, Mizuno N, Fukai K, Nakagawa K, Ishii M. 2004. Mild phenotype of familial cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour suppressor gene. Br J Dermatol 151:1084-1086. (Pubitemid 39573900)
79. Oosterkamp HM, Neering H, Nijman SM, Dirac AM, Mooi WJ, Bernards R, Brummelkamp TR. 2006. An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol 155:182-185. (Pubitemid 43876412)
80. Oranje AP, Halley D, den Hollander JC, Teepe RG, van de Graaf R, van den Ouweland A, Wagner A. 2008. Multiple familial trichoepithelioma and familial cylindroma: one cause! J Eur Acad Dermatol Venereol 22:1395-1396.
81. Pariser RJ. 1986. Multiple hereditary trichoepitheliomas and basal cell carcinomas. J Cutan Pathol 13:111-117. (Pubitemid 16047694)
82. Perkins ND. 2007. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8:49-62. (Pubitemid 46012014)
83. Pincus LB, McCalmont TH, Neuhaus IM, Kasper R, Oh DH. 2008. Basal cell carcinomas arising within multiple trichoepitheliomas. J Cutan Pathol 35 Suppl 1:59-64.
84. Pizinger K, Michal M. 2000. Malignant cylindroma in Brooke-Spiegler syndrome. Dermatology 201:255-257. (Pubitemid 30953201)
85. Poblete Gutierrez P, Eggermann T, Holler D, Jugert FK, Beermann T, Grussendorf-Conen EI, Zerres K, Merk HF, Frank J. 2002. Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J Invest Dermatol 119:527-531. (Pubitemid 35001967)
86. Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R, Huber M. 2003. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med 198:1959-1964. (Pubitemid 38032127)
87. Reiley W, Zhang M, Sun SC. 2004. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 279:55161-55167. (Pubitemid 40066510)
88. Reiley W, Zhang M, Wu X, Granger E, Sun SC. 2005. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol 25:3886-3895. (Pubitemid 40617640)
89. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, Sun SC. 2006. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 7:411-417.
90. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF, Leonard TO, Norbury CC, Fitzpatrick L, Zhang M, Sun SC. 2007. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 204:1475-1485. (Pubitemid 46919884)
91. Renatus M, Parrado SG, D'Arcy A, Eidhoff U, Gerhartz B, Hassiepen U, Pierrat B, Riedl R, Vinzenz D, Worpenberg S, Kroemer M. 2006. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14:1293-1302. (Pubitemid 44176373)
92. Saggar S, Chernoff KA, Lodha S, Horev L, Kohls S, Bonjo RS, Brandt HR, Hartmann K, Celebi JT. 2008. CYLD mutations in familial skin appendage tumours. J Med Genet 45:298-302. (Pubitemid 351685148)
93. Saito K, Kigawa T, Koshiba S, Sato K, Matsuo Y, Sakamoto A, Takagi T, Shirouzu M, Yabuki T, Nunokawa E, Seki E, Matsuda T, Aoki M, Miyata Y, Hirakawa N, Inoue M, Terada T, Nagase T, Kikuno R, Nakayama M, Ohara O, Tanaka A, Yokoyama S. 2004. The CAP-gly domain of CYLD associates with the prolinerich sequence in NEMO/IKKgamma. Structure 12:1719-1728. (Pubitemid 39200523)
94. Sakai A, Koga T, Lim JH, Jono H, Harada K, Szymanski E, Xu H, Kai H, Li JD. 2007. The bacterium, nontypeable Haemophilus influenzae, enhances host antiviral response by inducing toll-like receptor 7 expression: evidence for negative regulation of host anti-viral response by CYLD. FEBS J 274:3655-3668. (Pubitemid 47052404)
95. Salhi A, Bornholdt D, Oeffner F, Malik S, Heid E, Happle R, Grzeschik KH. 2004. Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene. Cancer Res 64:5113-5117. (Pubitemid 39006527)
96. Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT. 2003. Identification of a recurrent mutation in the CYLD gene in Brooke-Spiegler syndrome. Clin Exp Dermatol 28:539-541. (Pubitemid 37100561)
97. Song L, Rape M. 2008. Reverse the curse - the role of deubiquitination in cell cycle control. Curr Opin Cell Biol 20:156-163.
98. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. 2007. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 104:8869-8874. (Pubitemid 47175403)
99. Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, Turner H. 2006. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18:1584-1594. (Pubitemid 44236203)
100. Strobel P, Zettl A, Ren Z, Starostik P, Riedmiller H, Storkel S, Muller-Hermelink HK, Marx A. 2002. Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am J Surg Pathol 26:119-124. (Pubitemid 34020000)
101. Sun SC. 2008. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 8:501-511. (Pubitemid 351913677)
102. Takahashi M, Rapley E, Biggs PJ, Lakhani SR, Cooke D, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Vloten WA, Breuning MH, van den Ouweland A, Halley D, Delpech B, Cleveland M, Leigh I, Chapman P, Burn J, Hohl D, Gorog JP, Seal S, Mangion J. 2000. Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. Hum Genet 106:58-65. (Pubitemid 30156395)
103. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. 2003. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94:965-973. (Pubitemid 37508979)
104. Thomson SA, Rasmussen SA, Zhang J, Wallace MR. 1999. A new hereditary cylindromatosis family associated with CYLD1 on chromosome 16. Hum Genet 105:171-173. (Pubitemid 29396984)
105. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793-796. (Pubitemid 37021710)
106. Tsichritzis T, Gaentzsch PC, Kosmidis S, Brown AE, Skoulakis EM, Ligoxygakis P, Mosialos G. 2007. A Drosophila ortholog of the human cylindromatosis tumor suppressor gene regulates triglyceride content and antibacterial defense. Development 134:2605-2614. (Pubitemid 47225957)
107. Uede K, Yamamoto Y, Furukawa F. 2004. Brooke-Spiegler syndrome associated with cylindroma, trichoepithelioma, spiradenoma, and syringoma. J Dermatol 31:32-38. (Pubitemid 38197214)
108. van Balkom ID, Hennekam RC. 1994. Dermal eccrine cylindromatosis. J Med Genet 31:321-324. (Pubitemid 24127533)
109. Welch JP, Wells RS, Kerr CB. 1968. Ancell-Spiegler cylindromas (turban tumours) and Brooke-Fordyce trichoepitheliomas: evidence for a single genetic entity. J Med Genet 5:29-35.
110. Wooten MW, Geetha T, Babu JR, Seibenhener ML, Peng J, Cox N, Diaz-Meco MT, Moscat J. 2008. Essential role of sequestosome 1/p62 in regulating accumulation of Lys63-ubiquitinated proteins. J Biol Chem 283:6783-6789.
111. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M, Sun SC. 2007. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 13:705-716. (Pubitemid 350011985)
112. Xue L, Igaki T, Kuranaga E, Kanda H, Miura M, Xu T. 2007. Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila. Dev Cell 13:446-454. (Pubitemid 47308678)
113. Yoshida H, Jono H, Kai H, Li JD. 2005. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 280:41111-41121. (Pubitemid 41780606)
114. Young AL, Kellermayer R, Szigeti R, Teszas A, Azmi S, Celebi JT. 2006. CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes. Clin Genet 70:246-249. (Pubitemid 44219513)
115. Zhang XJ, Liang YH, He PP, Yang S, Wang HY, Chen JJ, Yuan WT, Xu SJ, Cui Y, Huang W. 2004. Identification of the cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma. J Invest Dermatol 122:658-664. (Pubitemid 38471333)
116. Zhang G, Huang Y, Yan K, Li W, Fan X, Liang Y, Sun L, Li H, Zhang S, Gao M, Du W, Yang S, Liu J, Zhang X. 2006a. Diverse phenotype of Brooke-Spiegler syndrome associated with a nonsense mutation in the CYLD tumor suppressor gene. Exp Dermatol 15:966-970. (Pubitemid 44688367)
117. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JM, Jain A. 2006b. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116:3042-3049. (Pubitemid 44684489)
118. Zhang M, Wu X, Lee AJ, Jin W, Chang M, Wright A, Imaizumi T, Sun SC. 2008. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem 283:18621-18626.
119. Zheng G, Hu L, Huang W, Chen K, Zhang X, Yang S, Sun J, Jiang Y, Luo G, Kong X. 2004. CYLD mutation causes multiple familial trichoepithelioma in three Chinese families. Hum Mutat 23:400.
120. Zhong S, Fields CR, Su N, Pan YX, Robertson KD. 2007. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26:2621-2634. (Pubitemid 46632003)
121. Zuo YG, Xu Y, Wang B, Liu YH, Qu T, Fang K, Ho MG. 2007. A novel mutation of CYLD in a Chinese family with multiple familial trichoepithelioma and no CYLD protein expression in the tumour tissue. Br J Dermatol 157:818-821. (Pubitemid 47389877)